Lupin to acquire two inhalation medicines from Sunovion Pharma for over Rs 623 crore
Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Mumbai: Global pharmaceutical major, Lupin Limited, today announced the signing of an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. for a purchase price of $75 million.
"Lupin expects the transaction to be accretive to earnings in the first year. The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S. and strengthens the company's presence in the respiratory therapy area while continuing to provide patients access to these important medicines," the company stated.
Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA) indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age or older with reversible obstructive airway disease.
Vinita Gupta, CEO, Lupin said, "We remain focused on strengthening our respiratory franchise in the U.S. We have established a strong position in the respiratory segment with our Albuterol MDI, and Brovana authorized generic launch. The addition of these two brands enhances our position in the segment."
Read also: Lupin Gets CDSCO Panel nod To study LUBT017 Biosimilar to Eylea
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.
